GOLDMAN SACHS GROUP INC - JOUNCE THERAPEUTICS INC ownership

JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 126 filers reported holding JOUNCE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.9%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of JOUNCE THERAPEUTICS INC
ValueSharesWeighting
Q1 2023$79,405
-43.6%
42,922
-66.1%
0.00%
Q4 2022$140,688
-62.8%
126,746
-21.5%
0.00%
Q3 2022$378,000
-39.0%
161,519
-21.1%
0.00%
Q2 2022$620,000
-76.7%
204,633
-47.8%
0.00%
-100.0%
Q1 2022$2,661,000
-55.8%
391,916
-45.6%
0.00%0.0%
Q4 2021$6,016,000
+20.2%
720,445
+6.9%
0.00%0.0%
Q3 2021$5,007,000
+347.9%
673,926
+310.1%
0.00%
Q2 2021$1,118,000
-28.1%
164,349
+8.6%
0.00%
Q1 2021$1,554,000
+524.1%
151,311
+325.7%
0.00%
Q4 2020$249,000
-19.7%
35,547
-6.7%
0.00%
Q3 2020$310,000
-20.9%
38,087
-33.0%
0.00%
Q2 2020$392,000
+3.2%
56,872
-28.9%
0.00%
Q1 2020$380,000
-60.8%
79,962
-27.9%
0.00%
Q4 2019$969,000
+112.5%
110,966
-18.9%
0.00%
Q3 2019$456,000
-1.7%
136,789
+46.0%
0.00%
Q2 2019$464,000
-17.1%
93,675
+3.7%
0.00%
Q1 2019$560,000
+74.5%
90,301
-5.2%
0.00%
Q4 2018$321,000
-51.4%
95,222
-6.4%
0.00%
Q3 2018$661,000
+2.8%
101,738
+21.1%
0.00%
Q2 2018$643,000
-62.5%
83,996
+9.4%
0.00%
Q1 2018$1,716,000
+117.8%
76,780
+24.3%
0.00%
Q4 2017$788,000
-56.0%
61,787
-46.3%
0.00%
Q3 2017$1,791,000
+83.3%
114,962
+65.1%
0.00%
Q2 2017$977,000
+260.5%
69,648
+465.7%
0.00%
Q1 2017$271,00012,3120.00%
Other shareholders
JOUNCE THERAPEUTICS INC shareholders Q4 2021
NameSharesValueWeighting ↓
TRV GP II, LLC 9,200,349$64,402,00044.86%
TRV GP III, LLC 3,048,780$21,342,0001.83%
SILVERARC CAPITAL MANAGEMENT, LLC 406,665$2,847,0001.65%
Sofinnova Investments, Inc. 925,280$6,477,0000.39%
Omega Fund Management, LLC 334,965$2,345,0000.35%
Yorktown Management & Research Co Inc 49,200$344,0000.31%
Woodline Partners LP 940,902$6,586,0000.18%
HUSSMAN STRATEGIC ADVISORS, INC. 51,000$357,0000.09%
HORIZON FINANCIAL SERVICES, LLC 12,005$84,0000.08%
Gyon Technologies Capital Management, LP 26,893$188,0000.06%
View complete list of JOUNCE THERAPEUTICS INC shareholders